심장이식 치료제 시장(2026-2030년)

The global heart transplantation therapeutics market is forecasted to grow by USD 133056.3 thousand during 2025-2030, accelerating at a CAGR of 3% during the forecast period. The report on the global heart transplantation therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of end-stage heart failure, technological advancements in organ preservation, breakthroughs in xenotransplantation and artificial heart technology.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global heart transplantation therapeutics market is segmented as below:

By Drug Class

• Immunosuppressants
• Anti-infectives
• Analgesics
• Others

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

By Type

• Left ventricular assist device (LVAD)
• Heart transplantation
• Implantable cardiac defibrillator (ICD)
• Extracorporeal membrane oxygenation (ECMO)

By Indication

• Ischemic heart disease (IHD)
• Dilated cardiomyopathy (DCM)
• Valvular heart disease (VHD)
• Hypertrophic cardiomyopathy (HCM)

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • The Netherlands
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the shift towards personalized immunosuppression and biomarker-guided therapy as one of the prime reasons driving the global heart transplantation therapeutics market growth during the next few years. Also, growing adoption of ex-vivo organ perfusion systems and emergence of novel biologics and cell-based therapies will lead to sizable demand in the market.

The report on the global heart transplantation therapeutics market covers the following areas:

• Global heart transplantation therapeutics market sizing
• Global heart transplantation therapeutics market forecast
• Global heart transplantation therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global heart transplantation therapeutics market vendors that include AbbVie Inc., Astellas Pharma Inc., Biocon Ltd., Dr. Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Jubilant Pharmova Ltd., LEO Pharma AS, Lupin Ltd., McKesson Corp., Novartis AG, Panacea Biotec Ltd., Pfizer Inc., RPG Life Sciences Ltd., Strides Pharma Ltd., Sun Pharmaceutical Industries, Teva Pharmaceutical Ltd.. Also, the global heart transplantation therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Drug Class
  • Executive Summary - Chart on Market Segmentation by Distribution Channel
  • Executive Summary - Chart on Market Segmentation by Type
  • Executive Summary - Chart on Market Segmentation by Indication
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Heart Transplantation Therapeutics Market 2020 - 2024
  • Historic Market Size - Data Table on Global Heart Transplantation Therapeutics Market 2020 - 2024 ($ thousand)
• 5.2 Drug Class segment analysis 2020 - 2024
  • Historic Market Size - Drug Class Segment 2020 - 2024 ($ thousand)
• 5.3 Distribution Channel segment analysis 2020 - 2024
  • Historic Market Size - Distribution Channel Segment 2020 - 2024 ($ thousand)
• 5.4 Type segment analysis 2020 - 2024
  • Historic Market Size - Type Segment 2020 - 2024 ($ thousand)
• 5.5 Indication segment analysis 2020 - 2024
  • Historic Market Size - Indication Segment 2020 - 2024 ($ thousand)
• 5.6 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ thousand)
• 5.7 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ thousand)

6 Qualitative Analysis

• 6.1 Impact of AI on Global Heart Transplantation Therapeutics Market
• 6.2 Impact of Geopolitical Conflict on Global Heart Transplantation Therapeutics Market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Drug Class

• 8.1 Market segments
• 8.2 Comparison by Drug Class
• 8.3 Immunosuppressants - Market size and forecast 2025-2030
• 8.4 Anti-infectives - Market size and forecast 2025-2030
• 8.5 Analgesics - Market size and forecast 2025-2030
• 8.6 Others - Market size and forecast 2025-2030
• 8.7 Market opportunity by Drug Class
  • Market opportunity by Drug Class ($ thousand)

9 Market Segmentation by Distribution Channel

• 9.1 Market segments
• 9.2 Comparison by Distribution Channel
• 9.3 Hospital pharmacies - Market size and forecast 2025-2030
• 9.4 Retail pharmacies - Market size and forecast 2025-2030
• 9.5 Online pharmacies - Market size and forecast 2025-2030
• 9.6 Market opportunity by Distribution Channel
  • Market opportunity by Distribution Channel ($ thousand)

10 Market Segmentation by Type

• 10.1 Market segments
• 10.2 Comparison by Type
• 10.3 Left ventricular assist device (LVAD) - Market size and forecast 2025-2030
• 10.4 Heart transplantation - Market size and forecast 2025-2030
• 10.5 Implantable cardiac defibrillator (ICD) - Market size and forecast 2025-2030
• 10.6 Extracorporeal membrane oxygenation (ECMO) - Market size and forecast 2025-2030
• 10.7 Market opportunity by Type
  • Market opportunity by Type ($ thousand)

11 Market Segmentation by Indication

• 11.1 Market segments
• 11.2 Comparison by Indication
• 11.3 Ischemic heart disease (IHD) - Market size and forecast 2025-2030
• 11.4 Dilated cardiomyopathy (DCM) - Market size and forecast 2025-2030
• 11.5 Valvular heart disease (VHD) - Market size and forecast 2025-2030
• 11.6 Hypertrophic cardiomyopathy (HCM) - Market size and forecast 2025-2030
• 11.7 Market opportunity by Indication
  • Market opportunity by Indication ($ thousand)

12 Customer Landscape

• 12.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

13 Geographic Landscape

• 13.1 Geographic segmentation
• 13.2 Geographic comparison
• 13.3 North America - Market size and forecast 2025-2030
  • 13.3.1 US - Market size and forecast 2025-2030
  • 13.3.2 Canada - Market size and forecast 2025-2030
  • 13.3.3 Mexico - Market size and forecast 2025-2030
• 13.4 Europe - Market size and forecast 2025-2030
  • 13.4.1 Germany - Market size and forecast 2025-2030
  • 13.4.2 France - Market size and forecast 2025-2030
  • 13.4.3 UK - Market size and forecast 2025-2030
  • 13.4.4 Italy - Market size and forecast 2025-2030
  • 13.4.5 Spain - Market size and forecast 2025-2030
  • 13.4.6 The Netherlands - Market size and forecast 2025-2030
• 13.5 Asia - Market size and forecast 2025-2030
  • 13.5.1 China - Market size and forecast 2025-2030
  • 13.5.2 Japan - Market size and forecast 2025-2030
  • 13.5.3 India - Market size and forecast 2025-2030
  • 13.5.4 South Korea - Market size and forecast 2025-2030
  • 13.5.5 Singapore - Market size and forecast 2025-2030
  • 13.5.6 Indonesia - Market size and forecast 2025-2030
• 13.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 13.6.1 Brazil - Market size and forecast 2025-2030
  • 13.6.2 Saudi Arabia - Market size and forecast 2025-2030
  • 13.6.3 South Africa - Market size and forecast 2025-2030
  • 13.6.4 Israel - Market size and forecast 2025-2030
  • 13.6.5 Argentina - Market size and forecast 2025-2030
  • 13.6.6 Egypt - Market size and forecast 2025-2030
  • 13.6.7 UAE - Market size and forecast 2025-2030
  • 13.6.8 Colombia - Market size and forecast 2025-2030
• 13.7 Market opportunity by geography
  • Market opportunity by geography ($ thousand)
  • Data Tables on Market opportunity by geography ($ thousand)

14 Drivers, Challenges, and Opportunity

• 14.1 Market drivers
  • Increasing prevalence of end-stage heart failure
  • Technological advancements in organ preservation
  • Breakthroughs in xenotransplantation and artificial heart technology
• 14.2 Market challenges
  • High risk of post-transplant complications
  • Shortage of donor organs
  • High cost of treatment
• 14.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 14.4 Market opportunities
  • Shift towards personalized immunosuppression and biomarker-guided therapy
  • Growing adoption of ex-vivo organ perfusion systems
  • Emergence of novel biologics and cell-based therapies

15 Competitive Landscape

• 15.1 Overview
• 15.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 15.3 Landscape disruption
  • Overview on factors of disruption
• 15.4 Industry risks
  • Impact of key risks on business

16 Competitive Analysis

• 16.1 Companies profiled
  • Companies covered
• 16.2 Company ranking index
  • Company ranking index
• 16.3 Market positioning of companies
  • Matrix on companies position and classification
• 16.4 AbbVie Inc.
  • AbbVie Inc. - Overview
  • AbbVie Inc. - Business segments
  • AbbVie Inc. - Key news
  • AbbVie Inc. - Key offerings
  • AbbVie Inc. - Segment focus
  • SWOT
• 16.5 Astellas Pharma Inc.
  • Astellas Pharma Inc. - Overview
  • Astellas Pharma Inc. - Product / Service
  • Astellas Pharma Inc. - Key news
  • Astellas Pharma Inc. - Key offerings
  • SWOT
• 16.6 Dr. Reddys Laboratories Ltd.
  • Dr. Reddys Laboratories Ltd. - Overview
  • Dr. Reddys Laboratories Ltd. - Business segments
  • Dr. Reddys Laboratories Ltd. - Key news
  • Dr. Reddys Laboratories Ltd. - Key offerings
  • Dr. Reddys Laboratories Ltd. - Segment focus
  • SWOT
• 16.7 F. Hoffmann La Roche Ltd.
  • F. Hoffmann La Roche Ltd. - Overview
  • F. Hoffmann La Roche Ltd. - Business segments
  • F. Hoffmann La Roche Ltd. - Key news
  • F. Hoffmann La Roche Ltd. - Key offerings
  • F. Hoffmann La Roche Ltd. - Segment focus
  • SWOT
• 16.8 GlaxoSmithKline Plc
  • GlaxoSmithKline Plc - Overview
  • GlaxoSmithKline Plc - Business segments
  • GlaxoSmithKline Plc - Key news
  • GlaxoSmithKline Plc - Key offerings
  • GlaxoSmithKline Plc - Segment focus
  • SWOT
• 16.9 Intas Pharmaceuticals Ltd.
  • Intas Pharmaceuticals Ltd. - Overview
  • Intas Pharmaceuticals Ltd. - Product / Service
  • Intas Pharmaceuticals Ltd. - Key offerings
  • SWOT
• 16.10 Jubilant Pharmova Ltd.
  • Jubilant Pharmova Ltd. - Overview
  • Jubilant Pharmova Ltd. - Business segments
  • Jubilant Pharmova Ltd. - Key offerings
  • Jubilant Pharmova Ltd. - Segment focus
  • SWOT
• 16.11 LEO Pharma AS
  • LEO Pharma AS - Overview
  • LEO Pharma AS - Product / Service
  • LEO Pharma AS - Key offerings
  • SWOT
• 16.12 Lupin Ltd.
  • Lupin Ltd. - Overview
  • Lupin Ltd. - Business segments
  • Lupin Ltd. - Key news
  • Lupin Ltd. - Key offerings
  • Lupin Ltd. - Segment focus
  • SWOT
• 16.13 McKesson Corp.
  • McKesson Corp. - Overview
  • McKesson Corp. - Business segments
  • McKesson Corp. - Key offerings
  • McKesson Corp. - Segment focus
  • SWOT
• 16.14 Novartis AG
  • Novartis AG - Overview
  • Novartis AG - Business segments
  • Novartis AG - Key news
  • Novartis AG - Key offerings
  • Novartis AG - Segment focus
  • SWOT
• 16.15 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Segment focus
  • SWOT
• 16.16 Strides Pharma Ltd.
  • Strides Pharma Ltd. - Overview
  • Strides Pharma Ltd. - Product / Service
  • Strides Pharma Ltd. - Key offerings
  • SWOT
• 16.17 Sun Pharmaceutical Industries
  • Sun Pharmaceutical Industries - Overview
  • Sun Pharmaceutical Industries - Business segments
  • Sun Pharmaceutical Industries - Key news
  • Sun Pharmaceutical Industries - Key offerings
  • Sun Pharmaceutical Industries - Segment focus
  • SWOT
• 16.18 Teva Pharmaceutical Ltd.
  • Teva Pharmaceutical Ltd. - Overview
  • Teva Pharmaceutical Ltd. - Business segments
  • Teva Pharmaceutical Ltd. - Key news
  • Teva Pharmaceutical Ltd. - Key offerings
  • Teva Pharmaceutical Ltd. - Segment focus
  • SWOT

17 Appendix

• 17.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 17.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 17.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 17.4 Research methodology
  • Research methodology
• 17.5 Data procurement
  • Information sources
• 17.6 Data validation
  • Data validation
• 17.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 17.8 Data synthesis
  • Data synthesis
• 17.9 360 degree market analysis
  • 360 degree market analysis
• 17.10 List of abbreviations
  • List of abbreviations